Health Net ruxolitinib Coverage Update

Coverage and Authorization Criteria

Initial Approval Criteria - MF

Covered when ALL of the following are met

Myelofibrosis initial criteria: Member has diagnosis of myelofibrosis (primary, post‑polycythemia vera, or post‑essential thrombocythemia); request is for oral ruxolitinib (Jakafi); prescribed by or in consultation with a hematologist or oncologist; recent platelet count documented within 30 days >= 50 x 10^9/L; age >= 18 years; member must use ruxolitinib if available unless contraindicated or clinically significant adverse effects occur; dosing meets one of the following: (a) new dose does not exceed both 50 mg per day and 2 tablets per day, OR (b) dose is supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence).

Initial Approval Criteria - PCV

Covered when ALL of the following are met

Polycythemia vera criteria: Member has diagnosis of polycythemia vera (PCV); request is for oral ruxolitinib (Jakafi); prescribed by or in consultation with a hematologist or oncologist; age >= 18 years; member must use ruxolitinib if available unless contraindicated or clinically significant adverse effects occur; failure of hydroxyurea, peginterferon, or interferon unless contraindicated or not tolerated; dosing meets one of the following: (a) new dose does not exceed both 50 mg per day and 2 tablets per day, OR (b) dose is supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence).

Initial Approval Criteria - GVHD

Covered when ALL of the following are met

GVHD criteria: Request is for oral ruxolitinib (Jakafi); diagnosis of steroid‑refractory acute or chronic graft‑versus‑host disease (GVHD) post hematopoietic cell transplantation; prescribed by or in consultation with an oncologist, hematologist, or bone marrow transplant specialist; age >= 12 years where specified by indication; member must use ruxolitinib if available unless contraindicated or clinically significant adverse effects occur; for acute GVHD: failure of a systemic corticosteroid as defined in Appendix D unless contraindicated; for chronic GVHD: failure of a systemic immunosuppressant (or other permitted prior therapy) unless contraindicated; Jakafi must not be prescribed concurrently with Imbruvica or Rezurock; dosing meets one of the following: (a) new dose does not exceed both 20 mg per day and 2 tablets per day, OR (b) dose is supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence).

Initial Approval Criteria - Off-label hematologic indications

Covered when ALL of the following are met for each off-label indication

MDS/MPN or CMML criteria: Diagnosis of chronic myelomonocytic leukemia (CMML) or other myelodysplastic/myeloproliferative neoplasm (MDS/MPN); request is for Jakafi; prescribed by or in consultation with a hematologist or oncologist; member must use ruxolitinib if available unless contraindicated; dosing is within FDA maximum limit for any FDA‑approved indication OR is supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence).

Pediatric Ph-like B-ALL criteria: Diagnosis of pediatric Ph‑like B‑cell acute lymphoblastic leukemia; request is for Jakafi; prescribed by or in consultation with a hematologist or oncologist; age < 18 years; prescribed in combination with an induction or consolidation regimen; tumor is positive for a JAK‑STAT pathway mutation, JAK2 fusion, EPOR rearrangement, SH2B3 alteration, or IL7R insertion/deletion; dosing is within FDA maximum limits or supported by guidelines/literature (prescriber must submit supporting evidence).

Myeloid/Lymphoid neoplasm with eosinophilia criteria: Diagnosis of a lymphoid, myeloid, or mixed‑lineage neoplasm with eosinophilia; request is for Jakafi; prescribed by or in consultation with a hematologist or oncologist; age > 18 years; tumor positive for a JAK2 mutation; dosing is within FDA maximum limits OR supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence).

Essential Thrombocythemia (off-label)

Covered when ALL of the following are met

ET_all: 1. Diagnosis of essential thrombocythemia; 2. Request is for Jakafi; 3. Prescribed by or in consultation with a hematologist or oncologist; 4. Age >= 18 years; 5. Member must use ruxolitinib if available unless contraindicated or clinically significant adverse effects occur; 6. Failure of hydroxyurea, peginterferon, interferon, or anagrelide unless contraindicated or not tolerated; 7. Dose is within FDA maximum limit for any FDA‑approved indication OR is supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence).

Prescriber must submit supporting evidence if dose is outside FDA limits or for off‑label dosing; Approval duration: Medicaid/HIM 6 months; Commercial 12 months or duration of request.

T-Cell Lymphomas (off-label)

Covered when ALL of the following are met

Tcell_all: 1. Diagnosis of T‑cell lymphoma; 2. Request is for Jakafi; 3. Prescribed by or in consultation with a hematologist or oncologist; 4. Age > 18 years; 5. Member must use ruxolitinib if available unless contraindicated or clinically significant adverse effects occur; 6. Prescribed either for palliative therapy OR after at least one line of systemic therapy (see Appendix B); 7. Dose is within FDA maximum limit for any FDA‑approved indication OR is supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence).

Approval duration: Medicaid/HIM 6 months; Commercial 12 months or duration of request.

Atopic Dermatitis (Opzelura)

Covered when ALL of the following are met

AD_all: 1. Diagnosis of atopic dermatitis (AD); 2. Affected body surface area (BSA) < 20%; 3. Request is for topical ruxolitinib (Opzelura); 4. Prescribed by or in consultation with a dermatologist or allergist; 5. Age >= 2 years; 6. Member is not immunocompromised; 7. Failure of two formulary medium‑to‑very high potency topical corticosteroids each used >= 2 weeks unless contraindicated; 8. Failure of a topical calcineurin inhibitor used >= 4 weeks unless contraindicated; 9. Failure of Eucrisa used >= 4 weeks unless contraindicated; 10. Opzelura is not prescribed concurrently with biologic medications (e.g., Dupixent, Adbry), other JAK inhibitors, or potent immunosuppressants; 11. Dose limits by age: age 2 to <12 years — one 60‑gram tube per 2 weeks; age >=12 years — one 60‑gram tube per week OR one 100‑gram tube per 2 weeks.

Approval duration AD: 8 weeks (continuation criteria specified).

Nonsegmental Vitiligo (Opzelura)

Covered when ALL of the following are met

NSV_all: 1. Diagnosis of nonsegmental vitiligo (NSV); 2. Total vitiligo involvement < 10% BSA; 3. Request is for topical ruxolitinib (Opzelura); 4. Prescribed by or in consultation with a dermatologist or allergist; 5. Age >= 12 years; 6. Failure of two formulary medium‑to‑very high potency topical corticosteroids in the previous 6 months unless contraindicated; 7. Failure of a topical calcineurin inhibitor used >= 4 weeks unless contraindicated; 8. Dose limits: one 60‑gram tube per week OR one 100‑gram tube per 2 weeks; 9. Opzelura is not prescribed concurrently with biologic medications or potent immunosuppressants.

Approval duration NSV: 6 months.

Immunotherapy-Related Toxicities (off-label)

Covered when ALL of the following are met

Immunotox_all: 1. Request is for Jakafi; 2. Prescribed by or in consultation with a hematologist or oncologist; 3. Age > 18 years; 4. For CAR T‑cell associated grade 4 cytokine release syndrome (CRS): failure of both high‑dose systemic corticosteroids and anti‑IL‑6 therapy unless contraindicated; 5. For immune checkpoint inhibitor‑associated concomitant myositis and myocarditis: Jakafi is prescribed in combination with abatacept; 6. Member must use ruxolitinib if available unless contraindicated; 7. Dose is within FDA maximum limits OR supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence).

Approval duration: CRS — 1 month; Myositis/myocarditis — 2 months; re‑authorization is not permitted for some immunotherapy‑related toxicities (see policy).

Continued Therapy

Covered continuation when specified criteria are met

ContTherapy_AD_NSV: A. For AD or NSV: member is currently receiving medication via the Centene benefit or previously met initial approval criteria; member is demonstrating clinical response (AD: reduction in itching/scratching; NSV: reduction in lesions); request is for Opzelura; Opzelura is not prescribed concurrently with prohibited biologics, other JAK inhibitors, or potent immunosuppressants; if request is for a dose increase, new dose does not exceed age‑based caps (see initial criteria).

ContTherapy_Immunotox: B. Immunotherapy‑related toxicities: re‑authorization is not permitted; members must meet initial approval criteria for a new authorization request.

ContTherapy_Other: C. All other indications: member is currently receiving medication via Centene benefit or has documentation of >= 30 days prior Jakafi use for a covered indication; request is for Jakafi; for GVHD, Jakafi is not prescribed concurrently with Imbruvica or Rezurock; if request is for a dose increase, new dose must meet one of the following: (a) for acute or chronic GVHD — new dose <= 20 mg/day (2 tablets), (b) for MF or PCV — new dose <= 50 mg/day (2 tablets), OR (c) new dose is supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence).

Dosing and indication mapping

Coverage references dosing by indication and restricts non‑FDA uses without supporting documentation

Dosing by indication: Ruxolitinib (Jakafi) dosing varies by indication: myelofibrosis starting dose based on platelet count (>200 x10^9/L: 20 mg PO BID; 100–200 x10^9/L: 15 mg PO BID; 50–<100 x10^9/L: 5 mg PO BID) with range 5–25 mg PO BID and maximum 50 mg/day; polycythemia vera starting dose 10 mg PO BID (max 50 mg/day); acute GVHD start 5 mg PO BID (max 20 mg/day); chronic GVHD start 10 mg PO BID (max 20 mg/day). Topical ruxolitinib (Opzelura): apply a thin layer twice daily to affected areas (AD up to 20% BSA; NSV up to 10% BSA) with pediatric gram limits and maximum topical dose options per product labeling (60 g/week or one 100‑gram tube per 2 weeks as specified). Non‑FDA approved indications require supporting evidence per off‑label use policies.

Selected Updated Coverage Criteria and Conditions

Notable covered/condition-specific updates and required clinical conditions per this document segment

Off-label NCCN additions: 1Q 2025: added off‑label indications per NCCN including immune‑checkpoint‑inhibitor‑associated concomitant myositis/myocarditis and T‑cell lymphoma; references reviewed and updated.

Opzelura topical use: Opzelura coverage updated to require affected BSA limits (AD <20% BSA; NSV <10% BSA), prohibit concurrent prescribing with biologics Dupixent or Adbry per FDA labeling, and revise topical maximum dosing per product information to allow 60 g/week or one 100‑gram tube per 2 weeks in specified circumstances (pediatric updates included).BSA <20% for AD

cGVHD oral ruxolitinib: For chronic GVHD, criteria updated to include failure of systemic immunosuppressants as an option for prior therapy; tablet quantity limit for oral ruxolitinib revised to 2 tablets per fill to align with twice‑daily regimen.

Use of Opzelura in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants (for example, azathioprine or cyclosporine) is not recommended. This limitation reflects the product's labeled statement and is intended to minimize additive immunosuppression and potential safety risks when topical ruxolitinib is combined with systemic immunomodulatory agents.

Indications that are not FDA‑approved and are not specifically addressed in this policy are excluded from authorization unless the provider submits sufficient supporting documentation of efficacy and safety in accordance with the payer's off‑label use policies (see CP.CPA.09, HIM.PA.154, CP PMN.53).

Authorization for off‑label ruxolitinib use requires submission of supporting clinical evidence (peer‑reviewed literature, guideline recommendations such as NCCN where applicable, or formulary/off‑label policy documentation) demonstrating the requested use is medically appropriate and safe for the member.

Per FDA labeling and policy updates, Opzelura must not be prescribed concurrently with the biologic agents Dupixent (dupilumab) or Adbry for atopic dermatitis or nonsegmental vitiligo. Concurrent prescribing with these biologics is specifically prohibited in the initial and continued therapy criteria and may lead to denial.

Requests that do not meet the stated approval criteria—such as lacking the required diagnosis, not being prescribed by or in consultation with the specified specialist, missing required laboratory documentation (for example, a recent platelet count where applicable), failure to document prior therapies when step therapy is required, or dosing that exceeds the policy limits without supporting evidence—are subject to denial. Providers must supply office notes, labs, and other clinical documentation to demonstrate all criteria are met.

Uses for indications not listed in this policy and for which the provider has not submitted adequate off‑label supporting documentation are considered not authorized and will generally be treated as not medically necessary.

Requests for non‑FDA indications that do not include the required off‑label support (e.g., literature, guideline endorsement, or payer off‑label policy justification) are subject to denial per the policy's off‑label exclusion rules.

For oral ruxolitinib requests for myelofibrosis (MF), the policy requires documentation of a recent platelet count of ≥ 50 x 10^9/L (reported within the last 30 days) in order to align with the product labeling and internal policy requirements; absence of this laboratory result may render the request inconsistent with policy and subject to denial.

Dosing, Formulations, and Quantity Limits

Regimen / Indication	Oral Jakafi Dosing (examples) / Limits
General rule
Dose must not exceed 50 mg/day and 2 tablets per day for indications other than GVHD unless supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence).

Indication	Regimen / Notes
CAR T-cell associated grade 4 CRS
Use Jakafi after failure of high‑dose systemic corticosteroids and anti‑IL‑6 therapy unless contraindicated; prior authorization for anti‑IL‑6 therapy may be required. Dose must be within FDA maximum limits or supported by guidelines/peer‑reviewed literature (submit evidence).
ICI-associated concomitant myositis/myocarditis
Jakafi prescribed in combination with abatacept for checkpoint inhibitor‑related myositis/myocarditis; dosing must be within FDA limits or supported by guidelines/peer‑reviewed literature (prescriber must submit supporting evidence).

Indication	Dose increase allowance / Rationale
Myelofibrosis (MF)
Dose increases up to a maximum of 50 mg/day are allowed when supported by FDA labeling, NCCN guidance, or peer‑reviewed literature; prescriber must submit supporting evidence for off‑label dose increases.
Polycythemia vera (PCV)
Dose increases up to a maximum of 50 mg/day are allowed when supported by guidelines or peer‑reviewed literature; prescriber must submit supporting evidence for off‑label dose increases.

Platelet count (x10^9/L)	Recommended Jakafi starting dose
> 200
20 mg PO twice daily
100–200
15 mg PO twice daily
50–<100
5 mg PO twice daily
Usable dose range
5–25 mg PO twice daily (range)
Maximum daily dose
50 mg/day

Indication	Starting dose / Maximum
Polycythemia vera (PCV)
Starting dose: 10 mg PO twice daily; Maximum dose: 50 mg/day

GVHD Type	Starting dose / Maximum
Acute GVHD
Starting dose: 5 mg PO twice daily; Maximum: 20 mg/day
Chronic GVHD
Starting dose: 10 mg PO twice daily; Maximum: 20 mg/day

Product (Opzelura)	Topical instructions / Limits
Opzelura (topical ruxolitinib)
Apply a thin layer twice daily to affected areas. For atopic dermatitis (AD) up to 20% BSA; for nonsegmental vitiligo (NSV) up to 10% BSA. Pediatric gram limits specified in dosing (age‑based weekly/biweekly tube limits).

Indication	Tablet quantity limit per fill (rationale)
Chronic GVHD (oral ruxolitinib)
Tablet quantity limited to 2 tablets per fill to align with twice‑daily regimen (policy revised to set tablet quantity limit at 2).

Topical limit (per PI)	Policy statement / Concurrent therapy
Maximum topical dosing
Per product prescribing information, maximum topical Opzelura dosing may be 60 grams per week or one 100‑gram tube per 2 weeks in specified circumstances (policy updated to include both options).
Concurrent therapy prohibition
Opzelura must not be prescribed concurrently with biologic medications Dupixent or Adbry for AD/NSV per FDA labeling; concurrent use with other JAK inhibitors or potent immunosuppressants is also not recommended.

Prior Authorization, Documentation, and Step Therapy

Prior Authorization

Prior Authorization Required

Prior authorization required. Provider must submit documentation (office notes, labs, etc.) supporting that the member meets all approval criteria. Failure to submit required documentation may result in denial.

Submit recent laboratory results when specified (e.g., platelet count within 30 days for myelofibrosis).
Provide clinical notes showing specialist involvement when required (hematologist/oncologist for hematologic indications; dermatologist/allergist for dermatologic indications).

Denial Risk

Non‑Covered / Off‑Label Indications Risk

Non‑FDA (off‑label) indications listed in this policy are only authorized when the request includes sufficient supporting evidence per applicable off‑label use policies (CP.CPA.09, HIM.PA.154, CP.PMN.53). Requests for indications not listed in this policy are at high risk of denial without adequate off‑label documentation.

Coding and Key Clinical Values

No explicit CPT/HCPCS/ICD-10/NDC codes listed in this sectionmixed

No codes listed

No explicit CPT/HCPCS/ICD/NDC codes listed in this segmentmixed

No codes listed

inv-23: Platelet count requirement — >= 50 x 10^9/L

Platelet count requirement>= 50 x 10^9/L (recent, within 30 days)

ContextRequired for initial myelofibrosis approval and reiterated in continued therapy notes

Source alignmentPolicy updated 1Q2023 to align with product PI and other myelofibrosis policies

inv-24: Body surface area (BSA) limits — Atopic dermatitis < 20% BSA; Nonsegmental vitiligo < 10% BSA

Atopic dermatitis BSA limit< 20% total body surface area (BSA)

Nonsegmental vitiligo BSA limit< 10% total BSA

Intended Line of Therapy

inv-52: second-line | later

second‑line | later

GVHD prior therapy: For GVHD: documentation of failure of a systemic corticosteroid for acute GVHD or failure of a systemic immunosuppressant for chronic GVHD (unless contraindicated) is required prior to Jakafi per policy.

inv-53: second-line | later

second‑line | later

PCV/ET prior therapy: For polycythemia vera and essential thrombocythemia: failure of hydroxyurea, peginterferon, or interferon (and anagrelide for ET) is required prior to Jakafi unless contraindicated or intolerant.

inv-54: second-line | palliative

second‑line | palliative

Genomic and Laboratory Requirements

inv-57: JAK-STAT pathway mutation / JAK2 fusion / EPOR rearrangement / SH2B3 alteration / IL7R insertion/deletion — biomarker list

Required biomarkers listJAK-STAT pathway mutation; JAK2 fusion; EPOR rearrangement; SH2B3 alteration; IL7R insertion/deletion

Indication linkageRequired for pediatric Ph-like B-cell ALL and referenced in off-label hematologic criteria

DocumentationPrescriber must submit supporting evidence when used for off-label indications

inv-58: JAK2 mutation — biomarker requirement note

JAK2 mutation requirementPositive JAK2 mutation required for myeloid/lymphoid neoplasm with eosinophilia off-label criteria

Applies toOff-label myeloid/lymphoid neoplasms with eosinophilia per policy

Definitions and Glossary

inv-45: Ruxolitinib — Janus kinase (JAK) inhibitor

Drug classJanus kinase (JAK) inhibitor

ProductsOral: Jakafi; Topical: Opzelura

Clinical uses (excerpt)Used for myelofibrosis, polycythemia vera, graft‑versus‑host disease, and topical dermatologic indications per policy

inv-46: Glossary — BSA, MF, CRS, NCCN, FDA abbreviations and short forms

BSABody surface area

MFMyelofibrosis

CRSCytokine release syndrome

Therapeutic Alternatives and Appendices

Note

Therapeutic alternatives: Appendix B lists preferred alternatives to consider before ruxolitinib

Appendix B lists preferred alternative therapies that may be considered or preferred before approval of ruxolitinib; providers should review Appendix B when preparing prior authorization requests.

Check Appendix B for the table of preferred alternatives and any prior authorization requirements
Be aware that listed alternatives may not be formulary for all lines of business

Ruxolitinib (Jakafi oral and Opzelura topical) is a Janus kinase (JAK) inhibitor with multiple FDA‑approved and off‑label hematology/dermatology uses; this policy provides indication‑specific criteria and limitations to ensure safe, evidence‑based use across covered lines of business.

Policy Revision History

2025-02-25annual_reviewLatest

1Q 2025 annual review: added off-label indications for immune-checkpoint-inhibitor-associated concomitant myositis/myocarditis and T-cell lymphoma per NCCN; references reviewed and updated.

2024-09-04policy_revision

Revised chronic GVHD tablet quantity limit to 2 per fill to align with twice-daily regimen.

2024-04-15policy_revision

OpenPayer

Clinical Policy: Ruxolitinib (Jakafi, Opzelura) - Coverage Criteria

Coverage and Authorization Criteria

Dosing, Formulations, and Quantity Limits

Prior Authorization, Documentation, and Step Therapy

Coding and Key Clinical Values

Intended Line of Therapy

Genomic and Laboratory Requirements

Definitions and Glossary

Therapeutic Alternatives and Appendices

Policy Revision History